Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/w4xxma59

PHARMACEUTICAL CARE IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND PHARMACO-ECONOMICAL BURDEN ON DIABETES PATIENT,COVID RECOVERED DIABETIC PATIENTS WITH CO-MORBID CONDITION.

Sadanandam Akari[1] , Sarumathy S[1*] ,

[1*]Department of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science & Technology, Kattankulathur, 603203, Chengalpattu, Tamil Nadu, India.
Email:- sarumats@srmist.edu.in

Corresponding Author:- Sarumathy S
Email:- sarumats@srmist.edu.in

Abstract:
The worldwide commonness of diabetes is supposed to reach 10.5% (536.6 million individuals) by 2021, proposing a clinical emergency. Overseeing individuals with diabetes with comorbidities and those without COVID-19 overburdens the personal satisfaction and economy. To address this, medical care experts with clinical mastery have been attempting to foster a more extensive job in the therapy of diabetes. In spite of the fact that there is proof that drug treatment further develops glucose control, little is had some significant awareness of its impacts on human results, for example, wellbeing related personal satisfaction (HRQoL). The ebb and flow study incorporates a writing search in data sets, for example, IDF, CINAHL, Medline, Embase, Pubmed and worldwide articles by September 2021, alongside the extent of diabetes pharmacological treatment. For diabetics. Until this point in time, a couple of distributions have been distributed that show the pharmacological advantage of pharmacotherapy. There is no information to help guarantees that PCs have any sure monetary effect. This article surveys distributed examinations on the monetary investigation of medication organization to increment drug worth and supports the case that drug organization assists a PC with diminishing the monetary weight of patient downfall. locally by decreasing medication related dreariness and mortality.

Key words: Diabetes, COVID recovered diabetic patients, Pharmaceutical care, Pharmacoeconomic, Quality of life

INTRODUCTION:

Pharmaceutical care:

The worldwide diabetes predominance in 2021 is supposed to be 10.5 percent (536.6 million individuals), showing a medical care emergency. The administration of diabetic patients with comorbidities, as well as sans covid diabetic patients, puts a weight on both personal satisfaction and financial matters. To address this, medical services experts with skill in meds have looked to foster a more extensive job in diabetes care. In spite of the fact that there is proof that pharmacological treatment improves glycemic control, less is known with respect to its effect on humanistic results, for example, wellbeing related personal satisfaction (HRQoL).The current study includes a literature

search in databases such as IDF, CINAHL, Medline, Embase, Pubmed, and international articles up until September 2021 to investigate the magnitude of pharmaceutical care and its impact on HRQoL in diabetic patients, as well as the pharmacoeconomic burden on diabetic patients. To date, only a few publications have been published indicating the pharmacological benefits of pharmacotherapy. There is no data to support claims that PCs have beneficial economic effects. This article reviews published studies relating to the economic analysis of drug administration in increasing drug value, and support for the claim that drug administration helps PC reduce the financial burden of a patient's decline. in the community by reducing drug-related morbidity and mortality.




Fig 1: Schematic representation of pharmaceutical care process

Table 1: Steps in pharmaceutical care process

The drug care process is a deliberate way to deal with patient consideration that involves a progression of moves toward ensure that patients will capitalize on their prescription treatment. The main moves toward giving drug care are as per the following:

1. ** Patient Assessment**: To distinguish potential drug related issues, the drug specialist looks at the patient's wellbeing, current prescriptions, and clinical history.
2. ** Recognizing a Medicine Treatment Issue (MTP)**: Expected MTPs, for example, insufficient prescription use, unfriendly medication responses, or drug cooperations, are distinguished by the drug specialist.
3. ** Interview fixated on the patient**: To look into the patient's side effects, treatment goals, and way of life propensities, the drug specialist leads a patient-focused interview.
4. ** Medication Reconciliation**: The drug specialist analyzes the patient's meds, including nutrients, natural enhancements, and solution and non-physician recommended meds, to find any errors or expected issues.
5. ** Improvement of a Restorative Plan**: A remedial arrangement is made by the drug specialist in view of the patient's clinical history, current prescriptions, wellbeing status, and any MTPs that have been recognized.
6. ** Requesting and Administering Medication**: Thinking about any evolved remedial arrangement, the drug specialist arranges and apportioning meds as endorsed.
7. ** Instruction of Patients**: The drug specialist clarifies for the patient how to take their prescriptions, likely aftereffects, and significant dosing data.
8. ** Follow-up**: The medication expert circles back to the patient to screen their response to treatment, recognize any probably issues, and make acclimations to the thoroughly examined plan contingent upon the circumstance.
9. ** Assessment and Monitoring**: The patient's reaction to treatment is consistently observed and

assessed by the drug specialist, who then, at that point, makes any important changes in accordance with the treatment intend to guarantee the most ideal results.
10. ** Communication**: The medication expert talks with other clinical consideration providers related with the patient's thought to ensure that all clinical consideration providers realize about the patient's remedy normal and any movements made.
11. ** Documentation**: All associations with the patient, including drug orders, patient instruction, and follow-up, are fastidiously reported by the drug specialist.

Drug specialists can give top notch drug care that assists patients with benefiting from their medicine treatment by following these means.




Figure 2: Steps in pharmaceutical care process

Diabetes:
Diabetes mellitus is a chronic endocrine condition that affects glucose, lipid, and protein metabolism. It develops when insulin is insufficient or absent, or when insulin function is impaired.

[20] (insulin resistance). Diabetes is portrayed by an imperfect or deficient insulin secretory reaction that prompts debilitated starch (glucose) use and hyperglycemia. [Twenty-one]

The World Prosperity Affiliation (WHO) introduced two terms, insulin-subordinate diabetes mellitus (IDDM) and non-insulin-subordinate diabetes mellitus (NIDDM), in 1980 and 1985, independently. Regardless, these terms have since been superseded by a more current portrayal structure that sees four specific sorts of diabetes.

The revived request structure, which was first introduced by the WHO in quite a while, diabetes into four sorts: type 1 (beforehand IDDM), type 2 (already NIDDM), "other express sorts", and gestational diabetes. This refreshed design was in like manner coordinated into the Overall Request of Afflictions (ICD) in 1992.

There are a couple of kinds of diabetes, which are gathered considering the essential causes, incidental effects, and treatment moves close. Here are the primary sorts of diabetes:

1. **Type 1 Diabetes (T1D)**: Generally called insulin-subordinate diabetes, this kind of diabetes is depicted by an all out shortfall of insulin creation. It is ordinarily broke down in kids and young adults, and is as often as possible treated with insulin treatment.
2. **Type 2 Diabetes (T2D)**: This is the most notable kind of diabetes, addressing around 90% of all cases. It is depicted by insulin impediment, where the body's cells become less responsive to insulin, and prevented insulin release. T2D is commonly dissected in adults and is habitually treated with lifestyle changes, such as eating routine and exercise, and oral solutions.
3. **Gestational Diabetes (GDM)**: This kind of diabetes makes during pregnancy, generally speaking, in the second or third trimester. It is depicted by high glucose levels that make in light of hormonal changes and insulin resistance. GDM commonly settle after pregnancy, but women who have had GDM are at extended imperil of making T2D in the not so distant future.
4. **LADA (Inactive Resistant framework Diabetes in Adults)**: This sort of diabetes is a kind of safe framework diabetes that is like T1D yet makes in adulthood. It is portrayed by a consistent diminishing in insulin creation long term.
5. **MODY (Improvement Starting Diabetes of the Young)**: This sort of diabetes is a phenomenal genetic issue that makes high glucose levels due deserts in the characteristics that oversee insulin creation. There are a couple subtypes of MODY, including MODY 1, MODY 2, and MODY 3.
6. **Secondary Diabetes**: This sort of diabetes makes due to another fundamental condition or ailment, as pancreatic damage or certain medications.
7. **Monogenic Diabetes**: This sort of diabetes is achieved by changes in a singular quality that impact insulin creation or action. There are a couple subtypes of monogenic diabetes, including neonatal diabetes and improvement starting diabetes of the young (MODY).
8. **Pancreatic Diabetes**: This sort of diabetes is achieved by damage to the pancreas, which can incite a lack of insulin-conveying beta cells.
9. **Cystic Fibrosis-Related Diabetes**: This sort of diabetes is ordinary in people with cystic fibrosis, a genetic issue that impacts the respiratory, stomach related, and conceptive structures.
10. **Diabetes Mellitus**: This term implies a social event of metabolic issues depicted by high glucose levels, including T1D, T2D, and various sorts of diabetes.

It's basic to observe that specific people could have a blend of these sorts of diabetes, or may have a kind of diabetes that doesn't get into one of these classes.
As per the International Diabetes Federation, around 537 million grown-ups (matured 20-79 years) will foster diabetes in 2021 [23], and the absolute number of individuals with diabetes will arrive at 643 million by 2030 and toward the finish of 2045 It ought to ascend to 783 million. Three out of four grown-ups with diabetes live in low-and center pay nations. Diabetes costs the US economy

something like $966 billion in medical **care costs, representing 9% of all grown-up spending.**




Figure 3: Estimated number of diabetics worldwide in 2021, 2030, 2045 (in Millions)

The top 10 countries (and 5 territories) in which diabetes is the most prevalent are listed below[24]




Figure.4: Pie diagram of Top 15 Countries with the Highest Rate of Diabetes (IDF 2021)

In India with population around 1,406,631,776 in 2022 the percentage of population with Diabetes 2021 is 10%, % undiagnosed is 10%, and percentage of population with Diabetes 2011 is 9**%.**

The World Prosperity Affiliation (WHO) has cultivated a total module on type 2 diabetes end and the board, which solidifies rules from various experts into a single report. The WHO has in like manner shipped off the Overall Diabetes More modest in April 2021, an overall drive highlighted further growing long stretch diabetes countering and care, with a specific focus on low-and focus pay countries.

The World Prosperity Get together has passed an objective in May 2021 highlighted further developing diabetes contravention and control. The resolution calls for action in several areas, including improving insulin access, promoting administrative coordination and harmonization for insulin and other diabetes-related medications and health products, and conducting a review of the feasibility and potential benefits of establishing an electronic platform to share data related to the

transparency of markets for diabetes medications and health products.

Personal satisfaction and its action:
In the administration of diabetes, personal satisfaction (QoL) is presently broadly perceived as a significant objective and result [26-28]. Definitions fluctuate, yet the most well-known is HRQoL, "an emotional viewpoint of their demeanor to life corresponding to their goals, assumptions, principles, and difficulties inside the setting of the way of life and values in which they live." [29-31]].
According to the patient's point of view, QoL investigation is helpful for concentrating on the social, profound, and actual impacts of medicines and sickness processes on everyday living. HRQoL is a multi-layered term that envelops physical, mental, and social working in an emotional evaluation of wellbeing and prosperity [32,33].
Most of QoL apparatuses depend on the improvement of polls fit for estimating how much handicap in different elements of a singular's life as emotionally experienced by that person. These surveys frequently incorporate inquiries (or things) concerning the patients' sentiments, as well as reaction options like yes/no, seven-or nine-point scales.
Scales, frequently alluded to as visual simple scales, are a kind of scale. Reactions to these inquiries are assembled into spaces or aspects (eg, physical or close to home working), which are then joined to give absolute scores.
Both the Diabetes Dependent Quality of Life Audit and the Diabetes Quality of Life Tools have been broadly explored and viewed as more significant and solid than DBA. The Short Form 36 (SF-36) is one of the most broadly utilized general wellbeing estimates in personal satisfaction research with demonstrated dependability and legitimacy. Its more limited length goes with the SF-12 a superior decision for general practice. The nature of the scale is resolved by its psychometric capacity, yet additionally by its subjective evaluation of the informational collection. [34] The Disease Impact Profile (SIP) and EuroQol EQ-5D are two different instruments. [35].
One more thorough survey of HRQoL markers utilized in diabetes studies incorporates the three most often utilized evaluations, a review of diabetes-based personal satisfaction (ADDQoL), a diabetic personal satisfaction (DQoL), and in general wellbeing . was recognized. Assessment. Be a personal satisfaction evaluation.

Contraptions used for individual fulfillment (QOL) evaluations are instruments that activity the overall success, satisfaction, and working of individuals with various conditions, including diabetes. The following are a couple of typical instruments used for QOL assessments:

1. **SF-12 (Short Design 12)**: A 12-thing review that activities physical and mental health related individual fulfillment.
2. **SF-36 (Short Construction 36)**: A 36-thing study that activities physical and profound prosperity associated individual fulfillment.
3. **EuroQol EQ-5D**: A 5-thing survey that activities prosperity related individual fulfillment in five viewpoints: flexibility, dealing with oneself, ordinary activities, torture/pain, and anxiety/despairing.
4. **RAND-36 (RAND Prosperity Study)**: A 36-thing survey that activities physical and close to home prosperity associated individual fulfillment.
5. **WHOQOL-BREF (World Prosperity Affiliation Individual fulfillment Brief)**: A 26-thing study that activities physical, mental, social associations, and normal pieces of individual fulfillment.
6. **Diabetes Individual fulfillment Overview (DQOL)**: A 32-thing survey that activities real secondary effects, near and dear working, and social assistance in people with diabetes.
7. **Diabetes Individual fulfillment Instrument (DQLI)**: A 29-thing overview that activities genuine secondary effects, significant working, and social assistance in people with diabetes.
8. **Medical Results Study (MOS) Short Construction Prosperity Outline (SF-12)**: A 12-thing

review that activities physical and mental prosperity associated individual fulfillment.
9. **Quality of Life in Diabetes (QOL-D)**: A 25-thing survey that activities real secondary effects, significant working, and social assistance in people with diabetes.
10. **Patient-Uncovered Results Assessment Information Structure (PROMIS)**: A broad system for assessing patient-point by point results, including genuine capacity, rest disrupting impact, and pressure.
These tools are widely used in clinical trials, research studies, and clinical practice to assess the impact of diabetes on patients' quality of life. By using these tools, healthcare providers can better understand the needs and concerns of patients with diabetes and develop more effective treatment plans to improve their overall well-being.

Pharmacoeconomics:
Pharmacoeconomics is a branch of health economics that examines and compares the costs (resources) and outcomes of pharmacological products and services.
The identification of various costs (i.e., monetary results) is the first stage in any cost study. These costs are usually classed as direct [39-44], indirect medical, or non-medical expenses [46-48].

In addition, there are intangible costs[49-51]. When these three types of charges are combined together, the most complete picture of actual medical costs emerges [52].
There are several types of costs that hospitals incur, including:
1. **Direct Costs**: These are costs that are directly related to the provision of patient care, such as:
* Labor costs (salaries and benefits of healthcare professionals)
* Materials and supplies (medications, equipment, etc.)
* Utilities and maintenance (electricity, water, etc.)
* Food and lodging (if patients require extended stays)
2. **Indirect Costs**: These are costs that are not directly related to patient care, but are still necessary for the hospital to operate efficiently, such as:
* Administrative costs (salaries and benefits of administrative staff)
* Marketing and advertising expenses
* Rent and maintenance of facilities
* Information technology costs
3. **Variable Costs**: These are costs that vary depending on the volume of patient care provided, such as:
* Labor costs for variable staffing needs
* Supplies and materials needed for specific treatments or procedures
* Equipment rental or purchase costs
4. **Fixed Costs**: These are costs that remain constant regardless of the volume of patient care provided, such as:
* Salaries and benefits of permanent staff
* Rent and maintenance of facilities
* Utilities and insurance costs
5. **Sunk Costs**: These are costs that have already been incurred and cannot be changed, such as:
* Past investments in equipment or technology
* Prior year's salaries and benefits
6. **Opportunity Costs**: These are costs that could have been earned if resources were used differently, such as:
* The cost of using a doctor's time to treat a patient instead of performing other tasks
* The cost of using hospital resources for one patient instead of another
7. **Capital Costs**: These are costs associated with the acquisition and maintenance of assets, such as:
* Purchasing or leasing equipment or buildings

* Maintenance and upgrade costs for existing equipment or buildings
8. **Human Resources Costs**: These are costs associated with hiring, training, and retaining employees, such as:
* Salaries and benefits
* Recruitment and training expenses
* Retention bonuses or incentives
9. **Information Technology Costs**: These are costs associated with maintaining and upgrading hospital information systems, such as:
* Software and hardware upgrades
* Network maintenance and security costs
* Training and support expenses
10. **Regulatory Compliance Costs**: These are costs associated with complying with government regulations and industry standards, such as:
* HIPAA compliance expenses
* Joint Commission accreditation fees
* OSHA compliance expenses

These sorts of costs can help centers with figuring out their money related situation and come to informed end results about resource assignment and arranging.

In clinical benefits monetary issues, costs can be assessed using various systems, for instance, cost per unit, cost per treatment, or cost per person. The choice of procedure depends upon whether a full scale or little costing approach is used. For instance, cost per individual every year, cost per case avoided, cost per life saved, cost per DALY (handicap changed life year), cost per QALY (quality-changed life year), and cost per LYG (life years procured) are ordinary estimations used in monetary assessment.

The outcome to be assessed is the expected benefit of an intervention. The goal is to assess the effects on a patient's life, including all pieces of significant worth and measure of life comprehensively.

One by and large used extent of significant worth and measure of life is the Quality Changed Life Year (QALY). Not set in stone by surveying a patient's future after a treatment or mediation and assessing the individual fulfillment principles for each year. This activity is much of the time used to survey the practicality of clinical consideration interventions.

The money related load of diabetes is tremendous, particularly in emerging countries. As the general population ages, the amount of people with diabetes should fabricate, inciting higher clinical consideration costs. Diabetes can in like manner have long stretch results, for instance, cardiovascular sickness, kidney mischief, and vision mishap, which can achieve extended clinical benefits costs.

The earnestness and length of diabetes, as well as the presence of comorbidities, can all impact the quick and distorted costs of diabetes. There is a basic uniqueness in the total spent on diabetes patients in made and arising countries.

To address the creating clinical consideration weight of diabetes, there is a prerequisite for expansive, supportive, and effective public clinical benefits workplaces. While drug therapy has been shown to unequivocally influence direct clinical consideration costs, further assessment with a greater degree is supposed to all the more promptly sort out the money related consequences of diabetes.

Table 4: Diabetic patients and health related expenditure

	2021	**2030**	**2045**

Adult population (million)	997	1,120	1,130
Diabetes (20-29 years)			
Regional Prevalence	11.30%	9.70%	11.30%
Age Prevalence	11.30%	12.20%	12.60%
Number of diabetic patients	88 million	115 million	153 million
Diabetes Mortality	1,150,300	-	-
Diabetes-related health expenditure			
Total health expenditure	8 billion	10 billion	12 billion

Medications are turning out to be more significant in medical services in most evolved nations, as the portion of medical care spending on drugs keeps on rising. Physician endorsed drug spending in the United States is developing at a speed of 12% each year and is supposed to develop at a pace of 10% each year for the following eight years. PC outcomes aren't positive all the time. Drug treatment issues (DTP)- related grimness and mortality cost large chunk of change consistently. Numerous trauma center visits and affirmations are brought about by DTPs, and most of them are preventable. Drug-related preventable incidental effects (PDRMs) frequently result from issues, for example, theabsence of a methodical system for checking patients getting prescription from medical care experts,instead of the inborn pharmacological properties of medications. As indicated by a Canadian report,the yearly expense of PDRM among more seasoned Canadians is $10.9 billion (Canadian) CND. Financial (drug and non-drug related) influences, clinical (clinical occasions, physiological and metabolic measures), and human (patient fulfillment) are three essential sorts of wellbeing results tobe assessed.

METHODS:

Search strategy:

The relevant articles are searched in databases including Pubmed by Medline, Embase, international articles, Cochrane and CINAH (June 2021 to September 2021). Key words includedsuch as 'India,' 'Diabetes Mellitus or Diabetes,' and so on., 'The terms 'Economic Burden,' 'Diabetes Costs,' Direct cost, 'Pharmacoeconomics,' 'Quality of life,' 'HRQOL,' 'Diabetes cost,' 'Direct and Indirect Costs,' 'Cost of illness Analysis,' 'Hospitalization cost of diabetes,' ' cost of Diabetic Complications,' 'Diabetes burden,'.

Articles published in English, papers within the objective's scope, articles with well described methodology, officially released documents, and neutral articles are chosen as inclusion

criteria.

Duplicate articles and those lacking verifiable proofs were rejected from the competition. The review was based on 90 of the 253 publications acquired for the project.




Figure 5: Prisma Flow chart

Discussion:

After reading abstracts and manually reviewing references, only a few articles addressing therapies provided by a physician or pharmacist alone or as part of a team and including HRQoL measurement were acceptable for inclusion in this review.In one study by Alsuwayt Saleh Iet al., where 274 patients were assessed, 54.4 percent of males reported better QoL than their female counterparts, despite the fact that general QoL among diabetic patients is low [65].

A cross-sectional review was embraced in India's Sub-Himalayan locale, with 300 patients involving a 34-thing scale QoL instrument for Indian Diabetes Patients (QoLID), which contains eight aspects.

Job limits attributable to actual wellbeing (RL), actual perseverance (PE), general wellbeing (GH), treatment fulfillment (TS), side effect botherness (SB), monetary concerns (FW), mental and close to home wellbeing (EMH), and diet counsel resistance are completely covered (DAT). In this examination, we found that being north of 55 years of age is a gamble factor for poor QoL [66].

The accompanying discoveries are upheld by the writing:

1. In diabetics, advanced age is related with diminished HRoL, particularly as far as actual wellbeing [67-68].
2. Ladies have been displayed to have a low quality of life because of error, disregard of treatment and follow-up, and absence of family and social help. These causes decrease personal satisfaction [69].

3.3. Patients with advanced education and higher financial status have a preferred personal satisfaction over patients with lower financial status [70,71].

Shanmugam Srira et al. directed a 8-month concentrate on the effect of medication treatment on patients' personal satisfaction in a confidential tertiary consideration showing clinic in South India, utilizing the Diabetes Treatment Satisfaction Questionnaire (DTSQ) to survey patient fulfillment with diabetes treatment. It comprises of six scale things that evaluate fulfillment with the treatment and two things that test the announced hyperglycemia and the recurrence of hypoglycemia. DTSQ components are evaluated on a size of 6 to 0. The ADDQOL and DTSQ surveys, which were satisfied and socially approved for use in the Indian populace, showed an improvement in diabetes-explicit wellbeing related personal satisfaction. When contrasted with the benchmark, patients with diabetes who were overseen by a clinical drug specialist had impressively diminished blood glucose and HbA1c values. Long haul drug specialist oversaw diabetic consideration administrations can bring about huge upgrades in diabetes patients' personal satisfaction and diabetes treatment fulfillment scores. The mediation gathering's improvement was featured by a decline in the patients' interests about what's to come, fears, and everyday environments [72].

YingQi et al. directed an imminent, multicenter, randomized controlled preliminary on 248 patients with glycosylated hemoglobin (HbA1c) > 7%, well established diabetes characterized as an illness length of something like 5 years, and polypharmacy characterized as taking at least 5 persistent medications. Patients in the mediation arm got standard group based pharmacological consideration, while patients in the control arm got care from a solitary doctor. The humanistic aftereffects of the patients were followed for a long time. In contrast with the control arm, the mediation arm showed huge upgrades in all out taking care of oneself (+0.36, 95% certainty stretch: [0.15, 0.73]), glycemic control (mean distinction: 0.44 percent, P =.003, 95% certainty span: [0.15, 0.73]), and blood glucose self-checking (+1.87, 95% certainty span: [1.00, 2.99], P =.001). Between the two arms, there were no tremendous contrasts in changes in diabetes-related personal satisfaction or by and large work hindrance. There was a huge contrast in action debilitation (impeded efficiency in standard neglected movement) between the two arms, with 43.3 percent disability in the benchmark group contrasted with 27.9 percent weakness in the mediation bunch (P =.047). Drug treatment given by a group upgraded complete taking care of oneself and glycemia without bringing down personal satisfaction or diminishing efficiency. [73]

In Pakistan, diabetes people partook in a one-month follow-up RCT. Fasting blood glucose (FBG) and irregular blood glucose (RBG), prescription adherence (MMAS), and wellbeing related personal satisfaction (HRQoL) are undeniably used to explore the impact of pharmacological treatment (EQ-5D-3L). Glycemic control, drug consistence, and HRQoL were all essentially better in both the control and mediation gatherings (p esteem 05). In any case, there was no genuinely huge distinction in blood glucose and HRQoL between the control and intervention gatherings (time compromise, TTO) [74].

Pharmacoeconomics:
It is a critical component in impacting the expense of DM treatment. Many investigations have been led to evaluate the wellbeing results and expenses of different helpful choices. The expense of treating diabetes and its ramifications incorporates the expense of medications, as well as different costs.

Investigations, costs for consultations, hospitalisation, and so on. As a result of these circumstances, drug prices have risen, making them unaffordable for a large number of patients.

Cost of diabetes and its complications:
The yearly quick cost per patient in India is $525.5. Diabetic patients in India will pay $24 per capita in direct costs. In India, hospitalization addresses 35% of diabetes patients' yearly prompt expenses, followed by 22% for noticing and labs, 17% for antidiabetic drugs, 3% for various medications, 12% for expert visits, and 3% for consumables. Patients spent a more conspicuous level of their clinical

benefits monetary arrangement on doctor embraced drugs than on other clinical advantages. Non-more seasoned diabetics cover the cost of suggested drug, 2% of hospitalizations, 9% of transient visits, and 28% of other help costs. Diabetic more settled individuals are responsible for paying for doctor supported drugs, 1% of hospitalizations, 8% of transient visits, and 31% of other assistance charges. The prompt and traffic circle expenses of diabetes overburden families, particularly needy individuals, who gain a few harder experiences treating CVDs and diabetes. As the inescapability of CVDs and diabetes climbs in India, more families will be affected, with the most un-lucky persevering through the most exceedingly terrible piece of the stack. According to recurring pattern research, diabetic patients in the north zone cost $254 every year, $142 every year in the south zone, $617 every year in the upper east zone, and $119 every year in the west zone (2020). Basically, the north zone's center deviant diabetes cost was $244 every year, while the south zone's cost was $16. The upper east zones gained $252 every year, while the west zones acquired $53 every year. Diabetes is responsible for 23.5 percent of the world's failure changed life years lost (DALYs), with a total indirect cost of $131 per individual for non-working diabetics and $227 per individual for working diabetics. An amount of $172 in meandering still up in the air. No matter what the way that family pay hardships were represented at $24, proficiency adversities in India totalled $123. Diminished effectiveness due to occupation related non-appearance, dull appearance at work and at home, joblessness as a result of serious failure, and early mortality cost the US $58 billion consistently.

Table 2 shows the prompt and underhanded costs of diabetes in India. (Various Regions)

India (Region)	**Cost**	
	Direct Cost	**Indirect Cost**
North Zone	$258	$248
South Zone	$145	$17
East Zone	$625	$255
West Zone	$120	$54

Table 3: Direct cost and Indirect cost of Diabetes Various Countries

Country	**Cost**	
	Direct Cost	**Indirect Cost**
USA	$237 billion	$90 billion
UK	$16.9 billion	$22.9 billion
China	$12,654 million	$387 million

As per the overview, most specialists (58%) find that the yearly difficult situation free diabetes goes from 10,000 to 40,000 INR ($136.87 to $547.50). (Figure 7A). As per 47% and 27% of specialists, the all out cost of hospitalization in a cardiovascular breakdown medical clinic in India is Rs 50,000-100,000 ($684.37-1368.75) and INR 1,0,000-2,0,00,000-2,00,000-2,000,000 - 2,0000-2,0000 INR ($1368.75 - $1368.7). † † (Figure 7B). Indeed, even on account of T2DM with renal disappointment, 51%, 23% and 22% of the doctors studied accepted that just 10%, 10% and 30%-half of patients on T2 dialysis could manage the cost of dialysis. (Figure 6) [75].




Figure 6: Patients can afford the cost of dialysis in T2DM




Fig 7: Economic burden of diabetic Patients

In 2019, a singular patient in South Korea spent a normal of US$4090 each year on diabetes treatment. Direct expenses per patient were assessed at US$2941 (71.9%) and above costs were assessed at US$1105 (28.1%) per patient. The all out monetary expense of diabetes in Korea is assessed at $18.293 billion. Most of all out costs (69.5%) are clinical costs, cost of lost efficiency (17.9% = 9.9% because of unexpected passing + 8.0% because of disease), cost of nursing staff (10.2%), and non-clinical costs (10.2%).) as follows. 10.2%). (2.4%). Albeit just 23.1% of diabetic patients are hospitalized (Table 5), clinical expenses address 42.7% of the complete financial expenses [76].

Table 5:Annual Cost in Type2 DM in South Korea

Expenses	Per Capita Cost,USD	Total Cost,million USD(%)
Direct Cost	2968	11,684(73.5)
Medical Cost	2864	11,278(71.0)
Nonmedical Cost	103	407(2.6)
Indirect Cost	1068	4204(26.5)
Caregiver's Cost	401	1579(9.9)
Productivity Loss Cost	667	2625(16.5)
Due to Morbidity	325	1279(8.0)
Due to Premature Mortality	342	1346(8.5)
Total	4035	15888(100)

In Sri Lanka, useful evaluations have been composed from a thriving framework viewpoint and the outcomes are recommended as hindrance changed future (DALYs). The expense and possible results of a 3-month raised LSM intercession (L-LSM) wandered from the yearly LSM intervention were gathered during a 3-year clinical starter (C-LSM). Exploratory evaluations of intervention costs, type 2 diabetes clinical advantages costs, and impeded DALYs showed that the P-LSM was more fiscally savvy than the C-LSM with a 57-78% expense reasonableness considering WHO clinical thought speculations. Direction for PRITIs. The more noticeable expense of a more noteworthy intervention was fairly offset the lower cost of intricacies of type 2 diabetes during the 3-year center around period. The ordinary expense contrast per part was LKR 188 (Bootstrap CI 107-484). The mean DALY for the uplifted mediation pack was 0.0013315 (SD 0.0108166), while the mean DALY for the benchmark bundle with less power was 0.0017329 (SD 0.0092226). Over the three-year time for testing, separating the expense adequacy separation of normal expense by the capability in commonplace impacts accomplished an ICER of LKR470,000 per DALY. [77]
In nations like the US (Direct cost: $11,744) and Germany (Direct cost: $4,713), China ($1,321), and Iran ($152) direct nonmedical utilizations give the time spent obtaining care, the vehicle charges to the crisis center, as well as the cost of food while in the crisis facility.

During COVID-19 pandemic, Diabetes with COVID Infected patients: The ongoing clinical management of COVID-19 diabetics in India shows that the overall death rate from COVID-19 in India is lower than the Indian approach, but diabetic patients are still at high risk. The following actions have been taken by the Public Health Service.

1. The need to reconnect with patients and strengthen diet and exercise education
2. Emphasize good control and allow for a change in treatment.
3. Involve a diabetologist in the care team
4. A protocol for local monitoring of blood glucose and insulin injections needs to be established. Further research is needed, especially on COVID-19 and cellular function.

Most previous studies revealed that diabetes with comorbidities resulted in slightly greater expenses [78-81]. Due to disease unawareness and uncontrolled blood sugar levels, the majority of COVID recovered patients are suffering from Black, White, and yellow fungus in a pandemic situation. Diabetes is linked to the development of severe COVID-19, and the higher risk among diabetics may have an impact on COVID-19 secondary care expenses [82-85]. During the first wave of COVID-19 in Europe, people with type 2 diabetes in good glycaemic control had a projected cost per hospital admission of EUR 25,018 compared to EUR 57,244 for people with type 1 diabetes in poor glycaemic control, reflecting a higher risk of critical care, ventilator support, and a longer hospital stay. In Europe, the overall direct expenses of COVID-19 secondarycare were anticipated to be EUR 13.9 billion. As a result, diabetes treatment accounted for 23.5 percent of total costs [86].
In this pandemic, diabetes patients are dealing with a slew of health issues, particularly COVID- free diabetics who are dealing with post-COVID sequelae such as black fungus, white fungus, andyellow

fungal infections [87-89]. After COVID recovery, early detection can reduce the pharmaco-economical cost on diabetic patients. In COVID recovery diabetes patients, pharmaceutical therapy can improve HRQoL[90].

CONCLUSION:

Pharmaceutical therapy and clinical pharmacy services that leverage the expertise of pharmacists in multidisciplinary and participatory patient care processes to improve clinical, economic and human patient outcomes, these services being included in the Indian health care system for educated and disease-knowledgeed patients it should be should be promoted And the result can reduce the risk of further problems and the financial burden.. This study suggests about the QoL indiabetes patients, pharmacocare effect on HRQoL, and pharmaco-economic burden on patients. The total cost of uncomplicated diabetes is over Rupees 40,000 (about $ 547.5) per year, and as complications increase, the cost of diabetes treatment increases. This study shows the pharmacological financial burden on diabetic patients with comorbidity.

REFERENCES:

1. Wermeille J, Bennie M, Brown I, McKnight J. Pharmaceutical care model for patients withtype 2 diabetes: Integration of the community pharmacist into the diabetes team - A pilot study. Pharm World Sci. 2004;26(1):18-25. doi:10.1023/B:PHAR.0000013465.24857.a8
2. Davis TME, Clifford RM, Davis WA, Batty KT. The role of pharmaceutical care in diabetes management. Br J Diabetes Vasc Dis. 2005;5(6):352-356. doi:10.1177/14746514050050061001
3. Borges APDS, Guidoni CM, Ferreira LD, Freitas O De, Pereira LRL. The pharmaceuticalcare of patients with type 2 diabetes mellitus. Pharm World Sci. 2010;32(6):730-736. doi:10.1007/s11096- 010-9428-3
4. Helper CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. American Journalof Hospital Pharmacists.1990; 47:533–43.
5. American Society of Hospital Pharmacists. ASHP statement on pharmaceutical care. American Journal of Hospital Pharmacy.1993; 50:1720–30.
6. De Sá Borges AP, Guidoni CM, de Freitas O, Pereira LRL. Avaliação econômica de pacientes ambulatoriais portadores de diabetes melito tipo 2 assistidos por um serviço de atenção farmacêutica. Arq Bras Endocrinol Metabol. 2011;55(9):686-691. doi:10.1590/S0004-27302011000900003
7. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: Updating the cost-of-illness model. J Am Pharm Assoc (Washington, DC 1996). 2001;41(2):192-199. doi:10.1016/S1086-5802(16)31229-3
8. Jameson JP, Baty PJ. Pharmacist Collaborative Management of poorly controlled diabetesmellitus: A randomized controlled trial. Am J Manag Care. 2010;16(4):250-255. AccessedSeptember 26, 2021. https://www.ajmc.com/view/ajmc_10apr_jameson_250to255
9. Krass I, Armour CL, Mitchell B, et al. The pharmacy diabetes care program: Assessment of a community pharmacy diabetes service model in Australia. Diabet Med. 2007;24(6):677-683. doi:10.1111/j.1464-5491.2007.02143.x
10. Mehuys E, Van Bortel L, De Bolle L, et al. Effectiveness of a community pharmacist intervention in diabetes care: A randomized controlled trial. J Clin Pharm Ther. 2011;36(5):602-613. doi:10.1111/j.1365-2710.2010.01218.x
11. Scott DM, Boyd ST, Stephan M, Augustine SC, Reardon TP. Outcomes of pharmacist- managed diabetes care services in a community health center. Am J Heal Pharm. 2006;63(21):2116-2122. doi:10.2146/ajhp060040
12. Royal S, Smeaton L, Avery AJ, Hurwitz B, Sheikh A. Interventions in primary care to reduce medication related adverse events and hospital admissions: Systematic review andmeta-analysis. Qual Saf Heal Care. 2006;15(1):23-31. doi:10.1136/qshc.2004.012153
13. Gæde P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a Multifactorial Intervention on

Mortality in Type 2 Diabetes. N Engl J Med. 2008;358(6):580-591. doi:10.1056/nejmoa0706245
14. Turner R, Holman R, Stratton I, et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J.1998;317(7160):703-713. doi:10.1136/bmj.317.7160.703
15. Kinge JM, Sælensminde K, Dieleman J, Vollset SE, Norheim OF. Economic losses and burden of disease by medical conditions in Norway. Health Policy (New York). 2017;121(6):691-698. doi:10.1016/j.healthpol.2017.03.020
16. Cohen LB, Taveira TH, Khatana SAM, Dooley AG, Pirraglia PA, Wu WC. Pharmacist- Led SharedMedical Appointments for Multiple Cardiovascular Risk Reduction in PatientsWith Type 2 Diabetes.Diabetes Educ. 2011;37(6):801-812.doi:10.1177/0145721711423980
17. Armour CL, Taylor SJ, Hourihan F, Smith C, Krass I. Implementation and evaluation of Australian pharmacists' diabetes care services. J Am Pharm Assoc. 2004;44(4):455-466. doi:10.1331/1544345041475625
18. Hae MC, Mitrovich S, Dubay D, Hayward RA, Krein SL, Vijan S. Proactive casemanagement of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: Arandomized controlled trial. Am J Manag Care. 2005;11(4):253-260. Accessed September 26, 2021. https://www.ajmc.com/view/apr05-2017p0253-0260
19. Davidson MB, Karlan VJ, Hair TL. Effect of a pharmacist-managed diabetes care programin a free medical clinic. Am J Med Qual. 2000;15(4):137-142. doi:10.1177/106286060001500403
20. Kumar CR. Basic Pathology, Prism PVT. Limited Bangalore, 5th edition, 1992, 569-587.
2. Ross and Wilson. Anatomy and Pathophysiology in Health and Illness, Churchill Livingstone Elsevier, 11th edition, 2010, 227-229
21. Kumar CR. Basic Pathology, Prism PVT. Limited Bangalore, 5th edition, 1992, 569-587.
22. DeFronzo RA, Bonadonna RC, Ferrannini E, Zimmet P. Pathogenesis of NIDDM,International Textbook of Diabetes Mellitus. 1997, 635-712
23. International Diabetes Federation (IDF) Diabetes Atlas – 10th ed. [cited 2021]. https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html
24. https://worldpopulationreview.com/country-rankings/diabetes-rates-by-country
25. HEARTS-D Module, https://www.who.int/publications/i/item/who-ucn-ncd-20.1
26. Chua SS, Kok LC, Md Yusof FA, et al. Pharmaceutical care issues identified by pharmacistsin patients with diabetes, hypertension or hyperlipidaemia in primary care settings. BMC Health Serv Res. 2012;12(1):1-10. doi:10.1186/1472-6963-12-388
27. Morgan CL, McEwan P, Morrissey M, Peters JR, Poole C, Currie CJ. Characterization andcomparisonof health-related utility in people with diabetes with various single and multiple vascular complications. Diabet Med. 2006;23(10):1100-1105.doi:10.1111/j.1464-5491.2006.01936.x
28. Pan CW, Sun HP, Zhou HJ, et al. Valuing health-related quality of life in type 2 diabetes patients inChina. Med Decis Mak. 2016;36(2):234-241. doi:10.1177/0272989X15606903
29. 29.Karimi M, Brazier J. Health, Health-Related Quality of Life, and Quality of Life: Whatis the Difference? Pharmacoeconomics. 2016;34(7):645-649. doi:10.1007/s40273-016- 0389-9
30. 30.Alonso J, Ferrer M, Gandek B, et al. Health-related quality of life associated with chronic conditions in eight countries: Results from the International Quality of Life Assessment (IQOLA) Project. Qual Life Res. 2004;13(2):283-298. doi:10.1023/B:QURE.0000018472.46236.05
31. DeSalvo KB, Bloser N, Reynolds K, He J, Muntner P. Mortality prediction with a single general self- rated health question: A meta-analysis. J Gen Intern Med. 2006;21(3):267- 275. doi:10.1111/j.1525-1497.2005.00291.x
32. .Grandy S, Fox KM. EQ-5D visual analog scale and utility index values in individuals withdiabetes and at risk for diabetes: Findings from the Study to Help Improve Early evaluationand management of risk factors Leading to Diabetes (SHIELD). Health Qual Life Outcomes. 2008;6:18. doi:10.1186/1477-7525-6-18

33. Holmes J, McGill S, Kind P, Bottomley J, Gillam S, Murphy M. Health-related quality oflife in type 2 diabetes (T2ARDIS-2). Value Heal. 2000;3(SUPPL. 1):47-51. doi:10.1046/j.1524-4733.2000.36028.x
34. Rajesh Nair, Paul Kanchan, Study performed in a private family practice clinic, Can Fam Physician,2017, 63(6) e310-e315.
35. Bentley JP, Smith MC, Banahan 3rd BF, Frate DA, Parks BR. Quality of life assessment by community pharmacists: an exploratory study. Qual Life Res 1998; 7: 175–86.
36. Koopmanschap M. Diabetologia Coping with Type 11 Diabetes: The Patient'sPerspective.; 2002.
37. 37.Wexler DJ, Grant RW, Wittenberg E, et al. Correlates of health-related quality of life in type 2 diabetes. Diabetologia. 2006;49(7):1489-1497. doi:10.1007/s00125-006-0249-9
38. 38.Venkataraman K, Wee HL, Leow MKS, et al. Associations between complications andhealth-related quality of life in individuals with diabetes. Clin Endocrinol (Oxf). 2013;78(6):865-873. doi:10.1111/j.1365-2265.2012.04480.x
39. Jacobson A, Barofsky I, Cleary P, Rand L. Reliability and validity of a diabetes quality-of-life measure of the Diabetes Control and Complications Trial (DCCT). Diabetes Care. 1988;11(9):725-732. doi:10.2337/diacare.11.9.725
40. Bradley C, Todd C, Gorton T, Symonds E, Martin A, Plowright R. The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: The ADDQoL. Qual Life Res. 1999;8(1-2):79-91. doi:10.1023/A:1026485130100
41. Power M, Kuyken W. World Health Organization Quality of Life Assessment (WHOQOL): Development and general psychometric properties. Soc Sci Med. 1998;46(12):1569-1585. doi:10.1016/S0277-9536(98)00009-4
42. Speight J, Reaney MD, Barnard KD. Not all roads lead to Rome - A review of quality of life measurement in adults with diabetes. Diabet Med. 2009;26(4):315-327. doi:10.1111/j.1464-5491.2009.02682.x
43. Mateti U, Kunduru B, Akari S. Health-care cost of diabetes in South India: A cost of illnessstudy. J Res Pharm Pract. 2013;2(3):114. doi:10.4103/2279-042x.122382
44. Kim TH, Chun KH, Kim HJ, et al. Direct medical costs for patients with type 2 diabetes and relatedcomplications: A prospective cohort study based on the korean national diabetes program. J KoreanMed Sci. 2012;27(8):876-882. doi:10.3346/jkms.2012.27.8.876
46. Blüher M, Kurz I, Dannenmaier S, Dworak M. Pill burden in patients with type 2 diabetesin Germany: Subanalysis from the prospective, noninterventional PROVIL study. Clin Diabetes. 2015;33(2):55-61. doi:10.2337/diaclin.33.2.55
47. Bernard DM, Banthin JS, Encinosa WE. Health care expenditure burdens among adults with diabetesin 2001. Med Care. 2006;44(3):210-215. doi:10.1097/01.mlr.0000199729.25503.60
48. Bansode B, Jungari DS. Economic burden of diabetic patients in India: A review. DiabetesMetab Syndr Clin Res Rev. 2019;13(4):2469-2472. doi:10.1016/j.dsx.2019.06.020
49. Suryavanshi MS, Yang Y. Incremental Burden on Quality of Life and Health Care Expenditures in Adults with Diabetes Complications: MEPS 2013–2015. J Gen Intern Med. 2019;34(6):812-814. doi:10.1007/s11606-019-04827-9
50. Rayappa PH, Raju K, Kapur A, Bjork S, Sylvest C, Kumar KMD. Economic cost of diabetes care: the Bangalore urban district diabetes study. Int J Diabet s Develpoping Ctries. 1999;19:87-97.
51. Dall TM, Zhang Y, Chen YJ, Quick WW, Yang WG, Fogli J. The economic burden of diabetes. Health Aff. 2010;29(2). doi:10.1377/hlthaff.2009.0155.
52. Bommer C, Heesemann E, Sagalova V, et al. The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study. Lancet Diabetes Endocrinol. 2017;5(6):423-430. doi:10.1016/S2213-8587(17)30097-9
53. Walley T, Haycox A. Pharmacoeconomics: basic concepts and terminology. Br J Clin Pharmacol. 1997;43(4):343-348. https://doi.org/10.1046/j.1365-2125.1997.00574.x
54. McIntosh E, Luengo-Fernandez R. Economic evaluation. Part 1: Introduction to the concepts of

economic evaluation in health care. J Fam Plann Reprod Health Care. 2006;32(2):107- 112. https://doi.org/10.1783/147118906776276549
55. Tonin FS, Aznar-Lou I, Pontinha VM, Pontarolo R, Fernandez-Llimos F. Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions. Pharmacy Practice 2021 Jan-Mar;19(1):2302.
56. 56. Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes: Estimatesfor the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-1053. doi:10.2337/diacare.27.5.1047
57. 57. Mohan D, Raj D, Shanthirani CS, et al. Awareness and knowledge of diabetes in Chennai - The Chennai Urban Rural Epidemiology Study [CURES - 9]. J Assoc Physicians India. 2005;53(APR):283-287.
58. 58. Rao MB, Prašek M, Metelko Ž. Organization of diabetes health care in Indian ruralareas. Diabetol Croat. 2002;31(3):161-171. Accessed September 24, 2021. https://web.archive.org/web/20180421100258id_/http://www.idb.hr/diabetologia/02no3- 3.pdf
59. Dall T, Mann SE, Zhang Y, et al. Economic costs of diabetes in the U.S. in 2007. DiabetesCare. 2008;31(3):596-615. doi:10.2337/dc08-9017
60. Chapman-Novakofski K. Epidemiology of Type 2 Diabetes. In: Nutraceuticals, GlycemicHealth andType 2 Diabetes. Vol 125. ; 2009:11-27. doi:10.1002/9780813804149.ch2
61. Kapur A. Economic analysis of diabetes care. Indian J Med Res. 2007;125(3):473-482.Accessed September 25, 2021. http://www.ijmr.org.in
62. Singh J. Economic burden of diabetes high globally. PharmacoEconomics OutcomesNews. 2017;777(1):12-12. doi:10.1007/s40274-017-3951-6
63. Solli O, Stavem K, Kristiansen IS. Health-related quality of life in diabetes: The associations of complications with EQ-5D scores. Health Qual Life Outcomes. 2010;8. doi:10.1186/1477-7525-8- 18
64. Guo X, Yao D, Liu J, Huang Y, Wang Y, Yao W. The current status of pharmaceutical care provisionin tertiary hospitals: Results of a cross-sectional survey in China. BMC Health Serv Res. 2020;20(1):1-9. doi:10.1186/s12913-020-05371-7
65. Alsuwayt Saleh; Almesned Mohammed; Alhajri Shahad; Alomari Naif; Alhadlaq Razan;Alotaibi Abdullah, Quality of life among type II diabetic patients attending the primary health centers of KingSaud Medical City in Riyadh, Saudi Arabia, Journal of Family Medicine and Primary Care, 2021,10(8),3040-3046, doi: 10.4103/jfmpc.jfmpc_175_21
66. Jyoti Gupta, Dheeraj Kapoor, Vivek sood., Quality of Life and its Determinants in Patientswith Diabetes Mellitus from Two Health Institutions of Sub-Himalayan Region of India, Indian J Endocrinol Metab, 2021 :25(3):211-219, doi:10.4103/ijem.IJEM_246_21
67. Pattankar TP, Patil SS. Assessment of quality of life among known type 2 diabetics – A community based cross sectional study study in north Karnataka. Natl J Community Med.2019;10:429–34
68. Somappa HK, Venkatesh M, Prasad R. Quality of life assessment among type 2 diabetic patients in rural tertiary center. Int J Med Sci Public Health. 2014;34:415–7
69. Gutch M, Mohd Razi S, Kumar S, Gupta KK. Diabetes mellitus: Trends in northern India.Indian. J Endocrinol Metab. 2014;8:731–4
70. Rajashekaran D, Kulkarni V, Unnikrishnan B, Kumar N, Holla R, Thapar R. Self-care activities among patients with diabetes attending a tertiary care hospital in Manglore, Karnataka, India. Ann Med Health Sci Res. 2015;5:59–64
71. Kiadaliri AA, Najafi B, Mirmalek-Sani M. Quality of life in people with diabetes: A systematic review of studies in Iran. J Diabetes Metab Disord. 2013;12:54
72. Shanmugam srira,, Lini Elzibeth Chack, Rajeshwari Ramasamy, Ali Ghasemi, Thengungal, Kochupapy Ravi and Ali Mohammad Sabzghabaee, Impact of pharmaceuticalcare on quality of life inpatients with type 2 diabetes mellitus, J Res Med Sci. 2011 Mar; 16(Suppl1): S412–S418.
73. Yingqi Xu ,Paul J. Gallagher D.,Cheryl W. Y. Tan .,Keith Y. K. Tsou , M.Med,David H.

Y. Tan , M.MeD,Henry Ramaya M.Med,, Impact of team based pharmaceutical care on the humanistic outcomes among patients with long standing diabetes: An interim analysis of a randomized, controlled, muilticenter study, Journal of the American college of clinical pharmacy,2021, https://doi.org/10.1002/jac5.1425

74. Muhammad Abubakar, Muhammad Atif, Impact of pharmacist led interventions on diabetes management at a community pharmacy in Pakistan:A randomized controlled trial,Inquiry2021, doi: 10.1177/00469580211036283
75. Kamal Sharma, A B. Chandorkar, Rajiv Kovil, S Venkataraman, KAV Subrahmanyam, Parthasarathi Mandal, Jasjeet Wasir, Mahesh Abhyankar, Ashish Prasad, Prashant S. Sarda, Expert Opinion About the Pharmacoeconomic Edge of Low- Cost Dapagliflozin in Type 2 Diabetes Mellitus in Indian Clinical Settings, 2021, Cureus 13(11): e19194, doi:10.7759/cureus.19194
76. Sung-Hee Oh, Hyemin Ku,and Kang Seo Park, Prevalence and socioeconomic burden of diabetes mellitus in South Korean adults: a population-based study using administrative data, BMC Public Health. 2021; 21: 548.
77. James Shearer, Miral Kalyani, Anastasios Mangelis, Dileep de Silva, Padmal de Silva, Mahen Wijesuriya & Janaka Karalliedde, Cost-Effectiveness of Peer-Educator– Delivered Lifestyle Modification for Type 2 Diabetes Prevention in a Young Healthy Population in Sri Lanka: A Trial-Based Economic Evaluation and Economic Model, PharmacoEconomics,2021, 5,693–700.
78. Yesudian CA, Grepstad M, Visintin E, Ferrario A. The economic burden of diabetes in India: A review of the literature. Global Health. 2014;10(1). doi:10.1186/s12992-014- 0080-x
79. COVID-19 Guidance | ABCD (Diabetes Care) Ltd. Association of British Clinical Diabetologists. Published February 2020. Accessed September 26, 2021. https://abcd.care/coronavirus
80. Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546-550. doi:10.1016/S2213- 8587(20)30152-2
81. Czernichow S, Bain SC, Capehorn M, et al. Costs of the COVID -19 pandemic associatedwith obesityin Europe: A health-care cost model. Clin Obes. 2021;11(2). doi:10.1111/cob.12442
82. Cariou B, Hadjadj S, Wargny M, et al. Phenotypic characteristics and prognosis ofinpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63(8):1500-1515. doi:10.1007/s00125-020-05180-x
83. Ogunleye OO, Basu D, Mueller D, et al. Response to the Novel Corona Virus (COVID- 19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future. FrontPharmacol. 2020;11. doi:10.3389/fphar.2020.01205
84. de Abajo FJ, Rodríguez-Martín S, Lerma V, et al. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-populationstudy. Lancet. 2020;395(10238):1705-1714. doi:10.1016/S0140-6736(20)31030-8
85. Kumar A, Arora A, Sharma P, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr Clin Res Rev. 2020;14(4):535-545. doi:10.1016/j.dsx.2020.04.044
86. Hirsch JS, Ng JH, Ross DW, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98(1):209-218. doi:10.1016/j.kint.2020.05.006
87. Singh AK, Singh R. Does poor glucose control increase the severity and mortality in patients with diabetes and COVID-19? Diabetes Metab Syndr Clin Res Rev. 2020;14(5):725-727. doi:10.1016/j.dsx.2020.05.037
88. WHO. The Impact of the COVID-19 Pandemic on Noncommunicable Disease Resources and Services: Results of a Rapid Assessment.; 2020. Accessed September 26, 2021. https://www.who.int/publications/i/item/ncds-covid-rapid-assessment
89. Ebekozien OA, Noor N, Gallagher MP, Alonso GT. Type 1 diabetes and covid-19: Preliminary findings from a multicenter surveillance study in the U.S. Diabetes Care. 2020;43(8):e83-e85.

doi:10.2337/dc20-1088

90. Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8(10):813-822. doi:10.1016/S2213-8587(20)30272-2